Piotr Popik1, Tomasz Kos, Magdalena Sowa-Kućma, Gabriel Nowak. 1. Behavioral Neuroscience and Drug Development, Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31-343 Kraków, Poland. nfpopik@cyf-kr.edu.pl
Abstract
RATIONALE: We investigated the immediate and enduring effects of ketamine in behavioral and neurochemical assays predictive of antidepressant activity. MATERIALS AND METHODS: One week after a single administration of ketamine (50-160 mg/kg), otherwise experimentally naive rats and mice were tested either in the forced swim test (FST) or the tail suspension test (TST). Other mice were also tested twice in the FST: immediately and 2 weeks after a single dose (1.25-50 mg/kg) of ketamine. In the next series of experiments, rats treated for 2 weeks twice daily with ketamine (50 or 160 mg/kg) or desipramine (10 mg/kg) were challenged with apomorphine and scored for locomotor activity and assayed for the density of cortical beta-adrenoceptors. The latter test was also carried out in rats that had received a single dose of ketamine (50 mg/kg) 1 week before the assay. The antidepressant-like (FST) and locomotor effects of ketamine (50 mg/kg) and desipramine (10 mg/kg) were assessed after their chronic (2 weeks, twice daily) administration as well. RESULTS: We report the lack of enduring antidepressant-like effect of ketamine in both rats and mice. A 2-week treatment with ketamine neither changed apomorphine-evoked locomotor hyperactivity nor did it decrease the density of cortical beta-adrenoceptors. However, some tolerance to the antidepressant-like effect of ketamine was noted in the FST, but it was accompanied by sensitization to its locomotor stimulatory effects. CONCLUSIONS: These data indicate that ketamine neither produces enduring antidepressant-like effects in rodents nor does it display antidepressant-like behavioral or neurochemical effects after chronic treatment.
RATIONALE: We investigated the immediate and enduring effects of ketamine in behavioral and neurochemical assays predictive of antidepressant activity. MATERIALS AND METHODS: One week after a single administration of ketamine (50-160 mg/kg), otherwise experimentally naive rats and mice were tested either in the forced swim test (FST) or the tail suspension test (TST). Other mice were also tested twice in the FST: immediately and 2 weeks after a single dose (1.25-50 mg/kg) of ketamine. In the next series of experiments, rats treated for 2 weeks twice daily with ketamine (50 or 160 mg/kg) or desipramine (10 mg/kg) were challenged with apomorphine and scored for locomotor activity and assayed for the density of cortical beta-adrenoceptors. The latter test was also carried out in rats that had received a single dose of ketamine (50 mg/kg) 1 week before the assay. The antidepressant-like (FST) and locomotor effects of ketamine (50 mg/kg) and desipramine (10 mg/kg) were assessed after their chronic (2 weeks, twice daily) administration as well. RESULTS: We report the lack of enduring antidepressant-like effect of ketamine in both rats and mice. A 2-week treatment with ketamine neither changed apomorphine-evoked locomotor hyperactivity nor did it decrease the density of cortical beta-adrenoceptors. However, some tolerance to the antidepressant-like effect of ketamine was noted in the FST, but it was accompanied by sensitization to its locomotor stimulatory effects. CONCLUSIONS: These data indicate that ketamine neither produces enduring antidepressant-like effects in rodents nor does it display antidepressant-like behavioral or neurochemical effects after chronic treatment.
Authors: Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji Journal: Biol Psychiatry Date: 2007-07-23 Impact factor: 13.382
Authors: Anita J Bechtholt-Gompf; Karen L Smith; Catherine S John; Hannah H Kang; William A Carlezon; Bruce M Cohen; Dost Ongür Journal: Psychopharmacology (Berl) Date: 2011-01-28 Impact factor: 4.530
Authors: Israel Garcia-Carachure; Francisco J Flores-Ramirez; Samuel A Castillo; Anapaula Themann; Miguel A Arenivar; Joshua Preciado-Piña; Arturo R Zavala; Mary Kay Lobo; Sergio D Iñiguez Journal: Neuropsychopharmacology Date: 2020-03-12 Impact factor: 7.853
Authors: Summer L Thompson; Amanda C Welch; Julia Iourinets; Stephanie C Dulawa Journal: Psychopharmacology (Berl) Date: 2020-01-11 Impact factor: 4.530
Authors: Rachel J Donahue; John W Muschamp; Scott J Russo; Eric J Nestler; William A Carlezon Journal: Biol Psychiatry Date: 2014-01-08 Impact factor: 13.382
Authors: Samantha A Gerb; Jemma E Cook; Alexandria E Gochenauer; Camille S Young; Lindak K Fulton; Andrew W Grady; Kevin B Freeman Journal: Comp Med Date: 2019-01-29 Impact factor: 0.982